NCT03269253 is a clinical trial in Eating Disorder, sponsored by Icahn School of Medicine at Mount Sinai.

Who is sponsoring NCT03269253?

NCT03269253 is sponsored by Icahn School of Medicine at Mount Sinai.

What condition does NCT03269253 study?

NCT03269253 studies Eating Disorder, Obesity.

Is NCT03269253 still recruiting?

NCT03269253 is currently completed. Last updated 31 August 2017.

Last reviewed 2017-08-31 · How we verify

NCT03269253

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Maternal Loss of Control Eating

Completed Last updated 31 August 2017

What this trial tests

trial in Eating Disorder in 14,451 participants. Completed in 20 July 2017.

Timeline

1 August 2016

Primary endpoint
20 July 2017

20 July 2017

Quick facts

Lead sponsor	Icahn School of Medicine at Mount Sinai
Status	Completed
Study type	OBSERVATIONAL
Enrollment	14,451
Start date	1 August 2016
Primary completion	20 July 2017
Estimated completion	20 July 2017
Sites	1 location across United States

Conditions studied

Eating Disorder — all drugs for Eating Disorder →
Obesity — all drugs for Obesity →

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

Adults 16 to 43, female only, with Eating Disorder or Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study focused on investigating the effects of maternal disordered eating on maternal and child outcomes as part of a secondary data analysis of the Avon Longitudinal Study of Parents and Children (ALSPAC).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Lack of iron, zinc, and vitamins as a contributor to the etiology of atopic diseases.
Peroni DG, Hufnagl K, Comberiati P, Roth-Walter F. · · 2022 · cited 56× · PMID 36698466 · DOI 10.3389/fnut.2022.1032481
Pregnancy loss of control over eating: a longitudinal study of maternal and child outcomes.
Micali N, Al Essimii H, Field AE, Treasure J. · · 2018 · cited 16× · PMID 29873682 · DOI 10.1093/ajcn/nqy040

Verify or expand the search:

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03269253 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
Last refreshed: 31 August 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03269253.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing